Literature DB >> 10075926

Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain.

N A Cacalano1, T S Migone, F Bazan, E P Hanson, M Chen, F Candotti, J J O'Shea, J A Johnston.   

Abstract

Signaling through the hematopoietic receptors requires activation of receptor-associated Janus (Jak) kinases. For example, Jak1 and Jak3 bind specifically to the IL-2 receptor beta (IL-2Rbeta) and common gamma (gammac) chains, respectively, and initiate biochemical signals critical in controlling immune responses. The region of Jak responsible for receptor interactions, however, is not well characterized. Here we describe a naturally occurring Jak3 mutation from a patient with autosomal severe combined immunodeficiency (SCID), where a single amino acid substitution, Y100C, in Janus homology domain 7 (JH7) prevents kinase-receptor interaction. This mutation also results in a loss of IL-2-induced signaling in a B-cell line derived from this patient. Using mutational analysis we have identified a region of Jak3, including portions of JH6 and JH7, that is sufficient for kinase-receptor contact and show that this segment interacts with the proline-rich Box1 region of the receptor. Furthermore, a Jak3-Jak1 chimera containing only the JH6 and JH7 domains of Jak3 interacts with gammac and can reconstitute IL-2-dependent responses, including receptor phosphorylation and activation of signal transducer and activator of transcription (STAT) 5b. Our results suggest that the N-terminus of Jak kinases is critical for receptor binding, and is therefore likely to determine specificity of Jak kinase-receptor interactions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10075926      PMCID: PMC1171243          DOI: 10.1093/emboj/18.6.1549

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  39 in total

1.  The amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha/beta receptor.

Authors:  M C Gauzzi; G Barbieri; M F Richter; G Uzé; L Ling; M Fellous; S Pellegrini
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

2.  IL2RGbase: a database of gamma c-chain defects causing human X-SCID.

Authors:  J M Puck
Journal:  Immunol Today       Date:  1996-11

3.  Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement.

Authors:  I Moarefi; M LaFevre-Bernt; F Sicheri; M Huse; C H Lee; J Kuriyan; W T Miller
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

Review 4.  The IFN gamma receptor: a paradigm for cytokine receptor signaling.

Authors:  E A Bach; M Aguet; R D Schreiber
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

5.  The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals.

Authors:  M Chen; A Cheng; Y Q Chen; A Hymel; E P Hanson; L Kimmel; Y Minami; T Taniguchi; P S Changelian; J J O'Shea
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

6.  Regulatory intramolecular association in a tyrosine kinase of the Tec family.

Authors:  A H Andreotti; S C Bunnell; S Feng; L J Berg; S L Schreiber
Journal:  Nature       Date:  1997-01-02       Impact factor: 49.962

7.  A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses.

Authors:  F Kohlhuber; N C Rogers; D Watling; J Feng; D Guschin; J Briscoe; B A Witthuhn; S V Kotenko; S Pestka; G R Stark; J N Ihle; I M Kerr
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

8.  A membrane-proximal region of the interleukin-2 receptor gamma c chain sufficient for Jak kinase activation and induction of proliferation in T cells.

Authors:  B H Nelson; J D Lord; P D Greenberg
Journal:  Mol Cell Biol       Date:  1996-01       Impact factor: 4.272

9.  T-lymphocyte differentiation and proliferation in the absence of the cytoplasmic tail of the common cytokine receptor gamma c chain in a severe combined immune deficiency X1 patient.

Authors:  E Morelon; A Dautry-Varsat; F Le Deist; S Hacein-Bay; A Fischer; G de Saint Basile
Journal:  Blood       Date:  1996-09-01       Impact factor: 22.113

10.  Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

Authors:  S M Russell; N Tayebi; H Nakajima; M C Riedy; J L Roberts; M J Aman; T S Migone; M Noguchi; M L Markert; R H Buckley; J J O'Shea; W J Leonard
Journal:  Science       Date:  1995-11-03       Impact factor: 47.728

View more
  24 in total

Review 1.  Interleukin-2 signaling and inherited immunodeficiency.

Authors:  N A Cacalano; J A Johnston
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

2.  Regulation of the Jak2 tyrosine kinase by its pseudokinase domain.

Authors:  P Saharinen; K Takaluoma; O Silvennoinen
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

Review 3.  Jaks and stats as therapeutic targets.

Authors:  J J O'Shea; R Visconti; T P Cheng; M Gadina
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 4.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

Review 5.  Therapeutic targeting of Janus kinases.

Authors:  Marko Pesu; Arian Laurence; Nandini Kishore; Samuel H Zwillich; Gary Chan; John J O'Shea
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

6.  Phosphorylation of Y372 is critical for Jak2 tyrosine kinase activation.

Authors:  Jacqueline Sayyah; Kavitha Gnanasambandan; Sushama Kamarajugadda; Shigeharu Tsuda; Jennifer Caldwell-Busby; Peter P Sayeski
Journal:  Cell Signal       Date:  2011-06-29       Impact factor: 4.315

Review 7.  The use of structural biology in Janus kinase targeted drug discovery.

Authors:  Nilda L Alicea-Velázquez; Titus J Boggon
Journal:  Curr Drug Targets       Date:  2011-04       Impact factor: 3.465

8.  Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2.

Authors:  Megumi Funakoshi-Tago; Stephane Pelletier; Tadashi Matsuda; Evan Parganas; James N Ihle
Journal:  EMBO J       Date:  2006-10-05       Impact factor: 11.598

9.  FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.

Authors:  Natalina E Elliott; Susan M Cleveland; Victor Grann; John Janik; Thomas A Waldmann; Utpal P Davé
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

10.  Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited.

Authors:  Sigrun R Hofmann; Albert Q Lam; Stephan Frank; Yong-Jie Zhou; Haydeé L Ramos; Yuka Kanno; Davide Agnello; Richard J Youle; John J O'Shea
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.